Type
- Laboratory test report (328)
- ARTG (257)
- Cancellation by sponsor (251)
- Australian Public Assessment Report (AusPAR) (30)
- Prescription medicine registration (29)
- Section 14, TGO91 consent (23)
- Prescription medicine decision summary (8)
- Designation or determination (7)
- Prescription medicine evaluation (2)
Date
- 2023 (8)
- 2022 (17)
- 2021 (118)
- 2020 (213)
- 2019 (154)
- 2018 (92)
- 2017 (78)
- 2016 (26)
- 2015 (14)
- 2014 (23)
- 2013 (8)
- 2012 (4)
- 2011 (1)
- 2010 (2)
- 2009 (16)
- 2008 (6)
- 2007 (14)
- 2006 (15)
- 2005 (15)
- 2004 (5)
- 2003 (7)
- 2002 (8)
- 2001 (5)
- 2000 (12)
- 1999 (6)
- 1998 (4)
- 1997 (2)
- 1996 (13)
- 1995 (3)
- 1994 (9)
- 1993 (7)
- 1992 (1)
- 1991 (29)
Results for
"[search-keyword]"
Sponsor content
935 result(s) found, displaying 1 to 10
- XenpozymePrescription medicine decision summaryXenpozyme (olipudase alfa) is approved for the treatment of non-central nervous system (CNS) manifestations of acid sphingomyelinase deficiency (ASMD).
- XENPOZYME olipudase alfa 20mg powder for injection vial (394103)ARTGAustralian Register of Therapeutic Goods (ARTG) information for XENPOZYME olipudase alfa 20mg powder for injection vial.
- DUPIXENT (Sanofi-Aventis Australia Pty Ltd)Prescription medicine registrationActive ingredients: dupilumab.
- AusPAR: VerorabAustralian Public Assessment Report (AusPAR)AusPAR for Verorab (inactivated rabies virus) for pre- and post-exposure prophylaxis against rabies.
- LIBTAYO (Sanofi-Aventis Australia Pty Ltd)Prescription medicine registrationActive ingredients: cemiplimab.
- Lantus Cartridge (407544)ARTGAustralian Register of Therapeutic Goods (ARTG) information for Lantus Cartridge.
- AusPAR: DupixentAustralian Public Assessment Report (AusPAR)AusPAR for DUPIXENT dupilumab for the treatment of asthma.
- Sanofi-Aventis Australia Pty Ltd - Specimen receptacle IVDs (402226)ARTGAustralian Register of Therapeutic Goods (ARTG) information for Sanofi-Aventis Australia Pty Ltd - Specimen receptacle IVDs.
- AusPAR: NexviazymeAustralian Public Assessment Report (AusPAR)AusPAR for NEXVIAZYME (avalglucosidase alfa) for long-term enzyme replacement therapy for the treatment of Pompe disease.
- BEYFORTUS Sanofi-Aventis Australia Pty LtdNov-2022Prescription medicine evaluationActive ingredient: nirsevimab.